Pioglitazone, a thiazolidinedione combined with imatinib, was effective in eliminating CML stem cells by inhibiting STAT5 through PPARγ activation [25]. The gene discussed is PPARG; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.